Andrew Callos - 17 Mar 2025 Form 4 Insider Report for CYTOKINETICS INC (CYTK)

Signature
/s/ John O. Faurescu, attorney-in-fact for Mr. Callos
Issuer symbol
CYTK
Transactions as of
17 Mar 2025
Transactions value $
-$457,292
Form type
4
Filing time
17 Mar 2025, 16:33:26 UTC
Previous filing
18 Mar 2025
Next filing
07 Apr 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYTK Common Stock Options Exercise $486K +20.9K +55.49% $23.26 58.6K 17 Mar 2025 Direct
transaction CYTK Common Stock Sale -$943K -20.9K -35.69% $45.14 37.7K 17 Mar 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYTK Non-Qualified Stock Option (Right to Buy) Options Exercise $0 -20.9K -13.94% $0.00 129K 17 Mar 2025 Common Stock 20.9K $23.26 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.